Sharescart Research Club logo
Products
Research
Tools
About
  • Home
  • /
  • Eris Lifesciences
Join Channel
Consolidated Standalone

Eris Lifesciences

₹1572.2 -20.5 | 1.3%

Market Cap ₹21415 Cr.

Stock P/E 57.2

P/B 7.2

Current Price ₹1572.2

Book Value ₹ 217.9

Face Value 1

52W High ₹1909.6

Dividend Yield 0.47%

52W Low ₹ 1130.1

Edit Ratio

Eris Lifesciences Research see more...

Overview Inc. Year: 2007Industry: Pharmaceuticals & Drugs

Eris Lifesciences Ltd is an totally India-based organisation, that is engaged in manufacturing, marketing and selling of generics in the chronic and acute classes of the Indian Pharmaceutical Market. The Company operates inside diverse regions via its seven targeted divisions: Eris, Nikkos, Adura, Montana, Inspira, Victus, Eris Kinedex, Eterna, and Altiza. Its Eris division consists of Atorsave 10, Atorsave 20, Decal, Enoxsave 0.6 and Metaloc XL100 merchandise; its Nikkos division consists of Alerfix, Erinac D, Ezeepam Plus 5, Zenpride OD and Nikotriol merchandise; its Adura division consists of Crevast 5, Glitaris M30, Metafort G1 CP and Olmin 10 products; its Montana department includes Meftaris, Calshine 60K Sachet, Hinder, Rabemon 20 and Vomisave Syrup merchandise; its Inspira department consists of Crevast F 5, Lnbeta 5 and Twichek merchandise, and its Victus department consists of Atorsave D80, Cyblex M 30 XR, Cyblex M 80, Cyblex M 60 XR and Cyblex MV 40.3 products.

Read More..

Eris Lifesciences Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Eris Lifesciences Quarterly Results

#(Fig in Cr.) Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 403 467 505 486 551 720 741 727 705 773
Other Income 1 1 3 4 15 2 5 4 8 3
Total Income 404 468 509 491 566 721 746 732 713 776
Total Expenditure 284 297 324 311 403 470 477 477 453 496
Operating Profit 120 171 185 180 164 252 269 255 260 279
Interest 9 17 16 18 33 60 59 57 54 49
Depreciation 35 41 42 46 54 76 80 81 77 71
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 76 112 126 116 77 116 129 116 129 160
Provision for Tax 14 19 4 14 -3 26 33 29 27 36
Profit After Tax 61 94 122 101 80 90 96 87 102 124
Adjustments 4 1 1 1 -9 -6 -5 -3 -8 -6
Profit After Adjustments 65 95 123 103 71 83 92 84 94 118
Adjusted Earnings Per Share 4.8 7 9.1 7.6 5.2 6.1 6.7 6.1 6.9 8.7

Eris Lifesciences Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 546 597 749 856 982 1074 1212 1347 1685 2009 2894 2946
Other Income 3 3 25 26 32 16 9 26 11 24 18 20
Total Income 549 600 775 882 1014 1090 1221 1373 1696 2033 2912 2967
Total Expenditure 424 425 480 533 637 706 781 862 1148 1334 1876 1903
Operating Profit 125 175 294 349 377 384 439 511 548 699 1036 1063
Interest 0 0 1 11 23 2 2 4 26 85 231 219
Depreciation 16 20 23 26 36 50 43 65 117 183 315 309
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 109 154 270 312 317 331 394 442 405 431 489 534
Provision for Tax 20 20 24 17 26 35 39 36 30 34 114 125
Profit After Tax 89 135 247 295 291 297 355 406 374 397 375 409
Adjustments -0 -1 0 -1 -0 -0 0 0 8 -5 -23 -22
Profit After Adjustments 89 134 247 294 291 296 355 406 382 392 352 388
Adjusted Earnings Per Share 6.5 9.7 17.9 21.4 21.1 21.8 26.2 29.9 28.1 28.8 25.8 28.4

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 44% 29% 22% 18%
Operating Profit CAGR 48% 27% 22% 24%
PAT CAGR -6% -3% 5% 15%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 19% 30% 25% NA%
ROE Average 14% 16% 19% 31%
ROCE Average 14% 14% 19% 32%

Eris Lifesciences Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 266 300 567 861 1151 1296 1576 1908 2196 2586 2854
Minority's Interest 4 3 24 25 18 0 0 -0 25 636 417
Borrowings 1 0 0 274 0 0 0 45 644 655 1738
Other Non-Current Liabilities 18 20 11 -26 -66 -80 -109 -124 86 325 363
Total Current Liabilities 65 69 129 294 377 220 235 283 521 2609 1490
Total Liabilities 354 392 732 1428 1481 1437 1703 2113 3472 6810 6862
Fixed Assets 72 71 232 771 761 875 854 918 2568 4319 5306
Other Non-Current Assets 119 98 231 290 67 27 313 484 61 112 225
Total Current Assets 163 222 269 367 653 535 536 711 843 2379 1331
Total Assets 354 392 732 1428 1481 1437 1703 2113 3472 6810 6862

Eris Lifesciences Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 7 5 9 2 11 8 67 37 51 56 94
Cash Flow from Operating Activities 90 131 200 235 223 271 375 378 292 486 1065
Cash Flow from Investing Activities -92 -44 -184 -590 -5 123 -323 -320 -982 -1855 -80
Cash Flow from Financing Activities 0 -84 -24 363 -221 -335 -82 -45 688 1380 -881
Net Cash Inflow / Outflow -2 4 -8 8 -3 60 -30 14 -2 11 104
Closing Cash & Cash Equivalent 5 9 2 11 8 67 37 51 56 94 200

Eris Lifesciences Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 6.47 9.68 17.95 21.39 21.15 21.84 26.16 29.88 28.1 28.83 25.83
CEPS(Rs) 7.59 0 19.59 23.32 23.81 25.54 29.32 34.61 36.12 42.62 50.67
DPS(Rs) 0 604.2 0 0 0 2.87 5.5 6.01 7.35 0 7.35
Book NAV/Share(Rs) 19.28 21.71 41.25 62.64 83.58 95.26 115.81 140.25 161.28 189.79 208.83
Core EBITDA Margin(%) 21.9 27.93 35.91 37.65 35.13 34.25 34.6 34.77 30.41 31.91 34.22
EBIT Margin(%) 19.74 25.17 36.22 37.74 34.66 31.06 31.85 32 24.41 24.41 24.23
Pre Tax Margin(%) 19.73 25.12 36.08 36.49 32.31 30.85 31.69 31.7 22.92 20.4 16.45
PAT Margin (%) 16.1 21.94 32.9 34.48 29.64 27.61 28.53 29.09 21.2 18.78 12.61
Cash Profit Margin (%) 18.9 25.25 35.94 37.47 33.34 32.29 31.98 33.73 27.83 27.41 23.22
ROA(%) 28.59 36.17 43.89 27.31 20.02 20.33 22.62 21.27 13.4 7.72 5.48
ROE(%) 40.3 47.68 56.9 41.3 28.96 24.28 24.78 23.33 18.25 16.64 13.81
ROCE(%) 49.25 54.56 62.56 35.76 26.54 25.44 27.6 25.29 17.3 12.37 13.59
Receivable days 15.14 14.56 18.07 24.64 27.99 40.93 43.59 39.44 46.91 61.68 54.07
Inventory Days 33.71 31.24 25.19 25.87 27.52 25.85 24.03 27.78 25.78 27.66 32.16
Payable days 135.59 113.55 86.17 166.67 207.67 195.95 155.23 155.58 125.63 165.04 140.91
PER(x) 0 0 0 37.15 30.46 16.88 23.11 23.06 20.36 29.18 54.83
Price/Book(x) 0 0 0 12.69 7.71 3.87 5.22 4.91 3.55 4.43 6.78
Dividend Yield(%) 0 0 0 0 0 0.78 0.91 0.87 1.28 0 0.52
EV/Net Sales(x) -0.01 -0.02 0.02 13.2 9.19 4.6 6.74 6.95 5.07 6.36 7.43
EV/Core EBITDA(x) -0.04 -0.05 0.04 32.4 23.96 12.86 18.59 18.31 15.61 18.29 20.75
Net Sales Growth(%) 7.22 9.43 25.54 14.16 14.79 9.36 12.83 11.15 25.1 19.23 44.02
EBIT Growth(%) 10.99 41.38 75.47 18.93 5.43 -1.99 18.83 12.6 -3.5 19.81 39.53
PAT Growth(%) 25.87 51.09 82.86 19.61 -1.3 1.84 19.77 14.26 -7.79 6.14 -5.65
EPS Growth(%) 26.05 49.69 85.43 19.17 -1.14 3.27 19.78 14.23 -5.94 2.58 -10.39
Debt/Equity(x) 0 0 0 0.44 0.15 0 0 0.02 0.38 1.06 0.85
Current Ratio(x) 2.5 3.22 2.08 1.25 1.73 2.43 2.27 2.51 1.62 0.91 0.89
Quick Ratio(x) 1.68 2.66 1.75 1.03 1.51 2.12 1.95 2.16 1.41 0.84 0.67
Interest Cover(x) 4974.41 558.56 246.14 30.31 14.76 145.25 200.75 105.81 16.46 6.09 3.11
Total Debt/Mcap(x) 0 0 0 0.03 0.02 0 0 0 0.11 0.24 0.13

Eris Lifesciences Shareholding Pattern

# Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
Promoter 52.86 54.91 54.9 54.9 54.88 54.87 54.86 54.85 54.83 54.85
FII 13.78 13.2 13.14 14.27 14.59 8.01 8.35 8.43 8.4 7.21
DII 10.74 14.53 14.56 15.63 16.23 18.64 18.06 18.07 18.17 19.36
Public 22.63 17.37 17.41 15.19 14.3 18.47 18.72 18.66 18.59 18.57
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Debtor days have improved from 165.04 to 140.91days.

Cons

  • Stock is trading at 7.2 times its book value.
  • The company has delivered a poor profit growth of 4% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Eris Lifesciences News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot Listing Price Listing Gain(%) Current Price Return (%) Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!